Haemonetics Corp. (HAE) Misses Q4 EPS by 3c; Guides FY13 EPS Below Views
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $102.92 --0%
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.5%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $186.7 million versus the consensus estimate of $183.09 million.
Haemonetics Corp. sees FY2013 EPS of $3.30-$3.40, versus the consensus of $3.50.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Haemonetics Corp. sees FY2013 EPS of $3.30-$3.40, versus the consensus of $3.50.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Merck (MRK) PT Raised to $170 at Guggenheim
- Citi upgrades Old Dominion Freight Line to Buy with $223 target
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
